Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review
- PMID: 34289899
- PMCID: PMC8296751
- DOI: 10.1186/s13054-021-03684-5
Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review
Abstract
Background: New-onset atrial fibrillation (NOAF) in patients treated on an intensive care unit (ICU) is common and associated with significant morbidity and mortality. We undertook a systematic scoping review to summarise comparative evidence to inform NOAF management for patients admitted to ICU.
Methods: We searched MEDLINE, EMBASE, CINAHL, Web of Science, OpenGrey, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, ISRCTN, ClinicalTrials.gov, EU Clinical Trials register, additional WHO ICTRP trial databases, and NIHR Clinical Trials Gateway in March 2019. We included studies evaluating treatment or prevention strategies for NOAF or acute anticoagulation in general medical, surgical or mixed adult ICUs. We extracted study details, population characteristics, intervention and comparator(s), methods addressing confounding, results, and recommendations for future research onto study-specific forms.
Results: Of 3,651 citations, 42 articles were eligible: 25 primary studies, 12 review articles and 5 surveys/opinion papers. Definitions of NOAF varied between NOAF lasting 30 s to NOAF lasting > 24 h. Only one comparative study investigated effects of anticoagulation. Evidence from small RCTs suggests calcium channel blockers (CCBs) result in slower rhythm control than beta blockers (1 study), and more cardiovascular instability than amiodarone (1 study). Evidence from 4 non-randomised studies suggests beta blocker and amiodarone therapy may be equivalent in respect to rhythm control. Beta blockers may be associated with improved survival compared to amiodarone, CCBs, and digoxin, though supporting evidence is subject to confounding. Currently, the limited evidence does not support therapeutic anticoagulation during ICU admission.
Conclusions: From the limited evidence available beta blockers or amiodarone may be superior to CCBs as first line therapy in undifferentiated patients in ICU. The little evidence available does not support therapeutic anticoagulation for NOAF whilst patients are critically ill. Consensus definitions for NOAF, rate and rhythm control are needed.
Keywords: Arrhythmia; Critical care; Intensive care; New onset atrial fibrillation; Scoping review; Stroke.
© 2021. The Author(s).
Conflict of interest statement
Paul Mouncey, Kathryn Rowan, and David Harrison have received grants from National Institute for Health Research. Peter Watkinson worked part time for Sensyne Health and has received grant funding from National Institute for Health Research, Wellcome, and Sensyne Health outside the submitted work. No other authors had competing interests to declare.
Figures
Similar articles
-
Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses.Health Technol Assess. 2021 Nov;25(71):1-174. doi: 10.3310/hta25710. Health Technol Assess. 2021. PMID: 34847987
-
Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review.BMJ Open. 2020 Mar 24;10(3):e034774. doi: 10.1136/bmjopen-2019-034774. BMJ Open. 2020. PMID: 32209631 Free PMC article.
-
Comparative effectiveness of common treatments for new-onset atrial fibrillation within the ICU: Accounting for physiological status.J Crit Care. 2022 Feb;67:149-156. doi: 10.1016/j.jcrc.2021.11.005. Epub 2021 Nov 16. J Crit Care. 2022. PMID: 34798373 Free PMC article.
-
Comparative Effectiveness of Heart Rate Control Medications for the Treatment of Sepsis-Associated Atrial Fibrillation.Chest. 2021 Apr;159(4):1452-1459. doi: 10.1016/j.chest.2020.10.049. Epub 2020 Oct 24. Chest. 2021. PMID: 33619010 Free PMC article.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
Cited by
-
Recognition of Strokes in the ICU: A Narrative Review.J Cardiovasc Dev Dis. 2023 Apr 21;10(4):182. doi: 10.3390/jcdd10040182. J Cardiovasc Dev Dis. 2023. PMID: 37103061 Free PMC article. Review.
-
Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review.J Clin Med. 2024 May 17;13(10):2951. doi: 10.3390/jcm13102951. J Clin Med. 2024. PMID: 38792492 Free PMC article. Review.
-
Study protocol: A systematic review and meta-analysis regarding the influence of coagulopathy and immune activation on new onset atrial fibrillation in patients with sepsis.PLoS One. 2023 Sep 8;18(9):e0290963. doi: 10.1371/journal.pone.0290963. eCollection 2023. PLoS One. 2023. Update in: PLoS One. 2025 Jan 29;20(1):e0318365. doi: 10.1371/journal.pone.0318365. PMID: 37683020 Free PMC article. Updated.
-
Comparison of rhythm and rate control medications for new-onset atrial fibrillation in septic patients: MIMIC-IV database analysis.J Transl Med. 2025 May 7;23(1):512. doi: 10.1186/s12967-025-06380-y. J Transl Med. 2025. PMID: 40336017 Free PMC article.
-
Research priorities for the study of atrial fibrillation during acute and critical illness: recommendations from the Symposium on Atrial Fibrillation in Acute and Critical Care.BMC Proc. 2024 Nov 5;18(Suppl 22):23. doi: 10.1186/s12919-024-00309-x. BMC Proc. 2024. PMID: 39497129 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical